Bone cancer pain is one of the most severe and intractable complications in patients suffering from primary or metastatic bone cancer and profoundly compromises the quality of life. Emerging evidence indicates that the dorsal root ganglion play an integral role in the modulation of pain hypersensitivity. However, the underlying molecular mechanisms during dorsal root ganglion-mediated bone cancer pain remain elusive. In this study, RNA-sequencing was used to detect the differentially expressed genes in dorsal root ganglion neurons of a rat bone cancer pain model established by intratibial inoculation of Walker 256 breast cancer cells. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis showed that the differentially expressed genes (fold change > 1.5; false discovery rate < 0.05) were enriched in the bone morphogenetic protein (BMP) signaling pathway, transforming growth factor-b signaling pathway, and positive regulation of cartilage development. Importantly, serum deprivation-response protein (Sdpr), hephaestin (Heph), transthyretin (Ttr), insulin receptor substrate 1 (Irs1), connective tissue growth factor (Ctgf ), and Bmp2 genes were associated with bone pain and degeneration. Of note, Bmp2, a pleiotropic and secreted molecule mediating pain and inflammation, was one of the most significantly upregulated genes in dorsal root ganglion neurons in this bone cancer pain model. Consistent with these data, upregulation of Bmp2 in the bone cancer pain model was validated by immunohistochemistry, real-time quantitative polymerase chain reaction, and western blotting. Importantly, intrathecal administration of siRNA significantly reduced Bmp2 transcription and ameliorated bone cancer pain in rat as shown by paw withdrawal mechanical threshold and spontaneous and movementevoked pain-like behaviors. In conclusion, we have characterized the comprehensive gene expression profile of dorsal root ganglion from a bone cancer pain rat model by RNA-sequencing and identified Bmp2 as a potential therapeutic target for bone cancer pain treatment.
Introduction
Various tumor types including breast, prostate, and lung carcinomas preferentially metastasize to the skeleton, where they induce significant bone remodeling, destruction, and bone cancer pain (BCP). [1] [2] [3] BCP is often severe and intractable and is a significant contributing factor to morbidity and loss of quality of life. 4 Most of the current pharmacological treatments provide nonselective relief for pain syndromes. Even for palliative radiotherapy, the rate of complete pain relief remains low. 5 Therefore, it is pivotal to investigate the pathogenesis of BCP and identify novel therapeutic targets for translational medicine. Inflammatory, neuropathic, and/or ischemic components have been reported to be involved in cancer-induced bone pain. 6 In rodent BCP models, bone metastasis of cancers alters the structure, physiology, and biochemistry of the bone and concurrently induces mechanical and inflammatory hyperalgesia. 7 In particular, hyperexcitability of nociceptive dorsal root ganglion (DRG) neurons is associated with inflammatory pain in rodent models. 8 Emerging evidence indicates that alterations in gene expression [9] [10] [11] [12] [13] [14] [15] and signaling pathways [16] [17] [18] contribute to induction and maintenance of BCP. For example, upregulation of P2X3 receptors, 9 sodium channels Nav1.8 13 and Nav1.9, 10 brain-derived neurotrophic factor, 11, 19 acid-sensing ion channel 3, 12 protease-activated receptor 2 and 4, 14 and activation of cAMP-PKA, 16 PI3K/Akt, 17 and Hedgehog signaling 18 were involved in DRG-mediated BCP in a rat model. Moreover, several studies have shown attenuation of BCP in rats. These studies included overexpression of suppressor of cytokine signaling 3 in DRG, 15 suppression of asparaginyl endopeptidase in cancer cells, intrathecal injection of genetically engineered human bone marrow stem cells expressing the proenkephalin gene, 20 and intraperitoneal administration of a somatostatin receptor type 4 selective agonist, J-2156. However, comprehensive gene expression profiling of DRGs in a BCP model has not been reported. Such profiling could help identify novel therapeutic targets for the relief of BCP.
In this study, next-generation RNA-sequencing (RNA-seq) was performed to detect the differentially expressed genes (DEGs) in DRGs from a rat BCP model. The results showed that DEGs were enriched in signaling pathways associated with bone pain, inflammation, and degeneration. In particular, Bmp2 was significantly increased in DRG neurons in a BCP rat model, and targeting of Bmp2 by siRNA ameliorated BCP in vivo, suggesting that Bmp2 may be an attractive therapeutic target for BCP.
Materials and methods

Animal husbandry
Female Sprague-Dawley rats (200 g-250 g, B&K Universal Group Limited) were used for this study. Animals were housed in separate cages at a temperature of 24 AE 1 C under a 12-h/12-h light-dark cycle and had free access to food and water. All animal procedures were carried out in accordance with the guidelines of the International Association for the Study of Pain 21 and were approved by the Animal Care and Use Committee of Shanghai Chest Hospital, Shanghai Jiao Tong University (Permission No. KS (Y)1616).
BCP model
The BCP model was established as previously described. 22 Briefly, three female Sprague-Dawley rats weighing 70 g to 80 g received an intraperitoneal inoculation of Walker 256 cells. After one week, cells in the ascites were collected and resuspended in saline to a final concentration of 2 Â 10 7 cells/mL. Then, female Sprague-Dawley rats weighing 200 g to 250 g were anesthetized with chloral hydrate (300 mg/kg, i.p.). A 23-gauge needle was inserted into the intramedullary canal of the left tibia, in the lower one third, to create a cavity for the injection of the cells, and 10 lL vehicle (sham group) or Walker 256 cells (2 Â 10 5 cells) (BCP group) were injected into the bone cavity. The cavity was sealed using bone wax prior to closure of the incision. The rats were returned to their home cages upon waking. Rats were sacrificed 21 days after tumor inoculation, and tibias were collected for gross examination.
Pain-related behaviors
Mechanical allodynia was determined by a significant decrease in the threshold of hind paw withdrawal to mechanical stimulation applied to the plantar surface of each hind paw. 23 Briefly, the animals were individually placed beneath an inverted ventilated cage with a metal-mesh floor. Von Frey monofilaments (0.6-, 1.0-, 1.4-, 2-, 4-, 6-, 8-, 10-, and 15-g), starting with 1 g and ending with 15 g in ascending order, were applied perpendicular to the plantar surface of each hind paw from beneath until the paw was withdrawn. The duration of each stimulus was approximately 2 s. Each monofilament was applied five times at 5-min intervals. Quick withdrawal or paw flinching was considered a positive response. The paw withdrawal mechanical frequency (PWMF) to each monofilament was calculated based on five applications. The paw withdrawal mechanical threshold (PWMT) was determined by the force at which PWMF ! 60%; 15 g was recorded as the PWMT if PWMF < 60% to all filaments.
Movement-evoked pain was assessed by limb use score. Rats were permitted to move spontaneously on a smooth plastic table (50 cm Â 50 cm). The limb use during spontaneous ambulation was scored on a scale of 4 to 0 (4. normal use; 3. slightly limping; 2. clearly limping; 1. no use of the limbs (partial); and 0. no use of the limbs (complete)).
RNA-seq
Rats were promptly sacrificed by cervical dislocation. L3-L5 DRGs were quickly harvested from sham and BCP rats (n ¼ 3). Total RNA was extracted from samples using TRIzol reagent (Invitrogen, Carlsbad, CA) and the integrity verified (Agilent 2100 bioanalyzer) prior to library construction. RNA-seq was performed using the Illumina HiSeq2000 platform. Sequencing reads were first filtered for adapter sequence, lowquality sequence and rRNA. Reads were then mapped to Human Genome GRCh38 (downloaded form GENCODE) using STAR Version 2.5.2. Gene expression was quantified by RSEM Version 1.2.31 and differentially expressed transcripts (false discovery rate < 0.05) were identified by EBSeq Version 1.10.0. Partek Genomics Suite and Gene Ontology Consortium (http://geneontology.org) were used for pathway and gene ontology enrichment analysis, respectively.
Western blotting
The expression of Bmp2 from sham and BCP mice was measured by western blot analysis. Rats were rapidly sacrificed by cervical dislocation. L3-L5 DRGs were quickly harvested and lysed; lysates were rotated for 2 h at 4 C, followed by centrifugation at 12,000 r/min for 15 min at 4 C. Supernatants were collected, and total protein concentration was titrated using a bicinchoninic acid kit. Equivalent amounts of protein (20 lg) were fractionated on 10% polyacrylamide gels. Proteins were transferred to nitrocellulose membranes (Millipore) at 100 mA for 90 min. Membranes were blocked with 5% nonfat milk in Tris-buffered saline (TBS) (50 mM Tris-HCl, 150 mM NaCl, pH 7.5) for 1 h at room temperature and incubated overnight at 4 C with primary antibody (anti-Bmp2 at 1:1000, Abcam) in TBS containing 1% milk. Following three washes with TBST, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:500, Abcam) in TBS containing 1% milk for 2 h at room temperature. Immunoreactive proteins were visualized using the enhanced chemiluminescence western blotting detection system (Santa Cruz). Membranes were subsequently stripped and reprobed for antib-actin antibody (1: 1000, Sigma). The chemiluminescent signal from the membranes was quantified by a GeneGenome HR scanner using GeneTools software (SynGene). Bmp2 protein expression was normalized to b-actin.
Real-time quantitative polymerase chain reaction
Rats were anesthetized with sodium pentobarbital (50 mg/kg i.p.), and the L3-L5 DRGs were quickly removed at the defined timepoint for each group. Total RNA was extracted using a total RNA Kit (invitrogen), and complementary DNA (cDNA) was generated using a cDNA Synthesis Kit (Promega, Madison, WI), according to the manufacturer's instructions. Real-time quantitative polymerase chain reaction (RT-qPCR) was carried out using a SYBR Green assay (Roche Ltd, Basel, Switzerland) and Rotor-Gene 3000 system (Corbett Research, Australia) based on the 2 -᭝᭝Ct method. b-actin was used as a housekeeping gene. The primer sequences for Bmp2 and b-actin were as follows: Bmp2: Sense: 5 0 -AAGCCAGGTGTCTCCA AG -3 0 ; Antisense: 5 0 -AAGTCCACATACAAAGGGT G-3 0 ; b-actin: Sense: 5 0 -ATGGTGGTATGGGTCAGA AGG-3 0 ; Antisense: 5 0 -TGGCTGGGGTGTTGAAG GTC-3 0 .
Immunohistochemistry
Animals were deeply anesthetized with sodium pentobarbital (50 mg/kg, i.p.) and underwent sternotomy, followed by intracardiac perfusion with 200 mL saline and 200 mL 4% ice-cold paraformaldehyde in 0.1 M phosphate-buffered saline. The spinal cord and L3-L5 DRGs were removed, postfixed in 4% paraformaldehyde for 4 h, and subsequently allowed to equilibrate in 30% sucrose in phosphate-buffered saline overnight at 4 C. Immunohistochemical analyses were performed with the Histostain-SP kit (Zymed, San Francisco, CA). After rehydration, inhibition of endogenous peroxidase with 3% hydrogen peroxide, and blocking (10% rabbit serum) for 30 min, the tissue sections were incubated with a specific antibody against Bmp2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) (1:500). Normal goat IgG was used as a negative control. The expression of Bmp2 was detected by a biotinstreptavidin-peroxidase system using diaminobenzidine as a chromogen. Counterstaining was performed with hematoxylin.
Targeting Bmp2 by siRNA in BCP model Bmp2 was targeted by siRNA (sequence: Sense: 5 0 -GA AGCCAUCGAGGAACUUUTT-3 0 , Antisense: 5 0 -A AAGUUCCUCGAUGGCUUCTT-3 0 ; GenePharma, Shanghai, China). Intrathecal administration of Bmp2-siRNA (2 lg siRNA-bone morphogenetic protein 2 (BMP2) or siRNA-negative control with in vivo-jet PEI (Invitrogen)) was performed seven days postinoculation of Walker 256 cells. In vivo Bmp2 knockdown efficiency from L4-L5 DRGs was examined by RT-qPCR. PWMT and movement-evoked pain from sham and BCP rats were monitored on day 4, 6, 8, 10, and 12 postintrathecal administration.
Statistics
Data are expressed as the mean AE SD for behavioral and molecular assays. Statistical analyses were conducted using SPSS statistics 18.0 software and included SNK and LSD test for two-sample data and analysis of variance for multiple comparisons where appropriate. A P value less than 0.05 was set as the level of statistical significance. Data and figures were organized using GraphPad 5.0 software.
Results
Pain behaviors of the rat BCP model
Rats inoculated with Walker 256 tumor cells displayed a gradual increase in sensitivity to Von Frey filament stimulation. On day 21 postinoculation of Walker 256 cancer cells, the PWMT from the BCP group decreased from the baseline level of 14.3 AE 1.4 g to 0.9 AE 0.3 g (Figure 1(a) ). The limb use score for the BCP group decreased from the baseline level (4.0AE0.0) to 0.3 AE 0.23 (Figure 1(b) ). The anatomic structure of the tibia appeared thicker, and palpable tumors were noted outside the bone upon gross examination of BCP rats 21 days postinoculation of Walker 256 cancer cells (Figure 1(c) ).
Gene expression profiling of DRG neurons from BCP rats by RNA-seq
RNA-seq of rat DRG neurons was performed after confirming the BCP phenotype by radiographic imaging and pain-related behavior measurement at day 21 postinoculation of Walker 256 cancer cells. Eighty DEGs (fold change (FC) > 1.5; false discovery rate < 0.05) were identified in the BCP group (n ¼ 3) compared to the sham group (45 upregulated and 35 downregulated). In silico functional analysis showed that 9 of these genes were associated with bone pain and 11 were associated with cancer development (Table 1 and Supplementary  Table 1 ). Gene ontology analysis showed that the DEGs were enriched in Golgi cisternae membrane and synaptic cleft (cellular component), SMAD binding and protein kinase C binding (molecular function), BMP signaling pathway, and cartilage condensation (biological process) (Figure 2(a) ). Kyoto Encyclopedia of Genes and Genomes analysis indicated that the Hippo, mTOR, and transforming growth factor (TGF)-b signaling pathways were activated, while steroid biosynthesis, vitamin digestion and absorption, and histidine metabolism were suppressed in DRG from the BCP group compared to the sham group (Figure 2(b) and (c)). In particular, Bmp2 (FC ¼ 2.09), BmP15 (FC ¼ 2.99), and Bmpr1b (FC ¼ 0.64) from the TGF-b superfamily were significantly increased in the BCP group.
Upregulation of Bmp2 in DRG is associated with BCP
Bmp2, similarly to other BMP family members, plays an important role in the development of bone and cartilage. Consistent with the RNA-seq data, upregulation of Bmp2 in BCP rats was further validated by immunohistochemistry (Figure 3(a) ), RT-qPCR (Figure 3(b) ), ELISA (Figure 3(c) ), and western blotting (Figure 3(d) ).
Targeting Bmp2 ameliorates BCP in vivo
Information arising from RNA-seq data and subsequent validation prompted us to further investigate the role of Bmp2 upregulation during BCP hypersensitivity. Bmp2 was targeted by siRNAs in BCP rats. Targeting by siRNA resulted in significantly reduced Bmp2 transcription (Figure 4(a) ) and ameliorated BCP in rats as indicated by increased PWMT levels (Figure 4(b) ) at day 4, 6, 8, 10, and 12 postintrathecal siRNA administration. Consistently, limb use scores were also increased in BCP rats at day 6, 8, and 10 postintrathecal Bmp2-siRNA administration (Figure 4(c) ). These data indicated that Bmp2 antagonists may be effective for BCP treatment in vivo.
Discussion
Primary and metastatic cancers that affect the bone are frequently associated with severe and intractable BCP including nociceptive, neuropathic, and inflammatory pain. 1, 24 Although the etiology of BCP remains unclear, animal models of BCP make it possible to unravel neuropathological processes that occur in the region of tumor growth. In recent years, next-generation sequencing including RNA-seq has been used to analyze the cellular transcriptome for mechanistic study and translational medicine. However, gene expression profiling by RNA-seq of DRGs during BCP and peripheral hypersensitivity has not been reported. Here, we made use of RNA-seq and identified eighty DEGs in DRGs from BCP compared to sham rats. Functional annotation showed that nine of the DEGs were associated with bone pain. For example, Ttr mutation was associated with familial amyloid polyneuropathy and refractory neuropathic pain. 25, 26 Sdpr was reported to be increased in peripheral inflammatory pain. 27 In addition, eleven DEGs were associated with cancer development, suggesting that the alterations in these genes may play important roles in cancer metastasis. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analysis showed that the DEGs were enriched in the Hippo, mTOR, and TGF-b signaling pathways and associated with inflammation, enzyme activity, synaptic cleft, etc.
In previous studies of BCP, 28 dorsal horn activation of mTOR was shown to participate in N-methyl-D-aspartate receptor-triggered dorsal central sensitization. In addition, previous studies 29 have found that TGF-b1 is highly expressed in tumor-bearing bone, where it contributes to BCP via the upregulation and sensitization of transient receptor potential vanilloid type 1 in primary sensory neurons.
BMPs are a group of growth and morphogenetic factors originally discovered by their ability to induce the formation of bone and cartilage. Among the BMP family members, BMP2-7 belongs to the TGF-b superfamily of proteins. BMP2, 4, 6, and 7 are commonly referred to as the osteogenic BMPs, based on their potent bone-inducing activity. 30 BMP3 is a negative regulator of bone density. 31 BMP4 is an important factor in early nervous system development and regeneration after injury and a critical mediator of adult physiological plasticity. 32 In this study, we found that Bmp2 was significantly increased in DRGs from a rat BCP model. Notably, Bmp2 is involved in the Hedgehog and TGF-b signaling pathways and in cytokine-cytokine receptor interactions important for cell proliferation, adhesion, migration, and apoptosis. BMP targeting, either through deletion of BMP coreceptor RGMb or BMP antagonist Noggin, retarded early axonal regeneration after sciatic nerve crush injury. 33 Moreover, implantation of recombinant human BMP2 in lumbar spine triggered potent neuroinflammatory responses in the DRGs. 34 However, the role of Bmp2 in DRGs during peripheral hypersensitivity of BCP was unknown.
There are several limitations for the current study. First, we did not include double labeling of the nociceptive neurons and Bmp2 in the immunohistochemical analyses. Therefore, it is unknown whether Bmp2 is specifically expressed in nociceptive DRG neurons. Second, our assessment of siRNA efficiency by mRNA expression analysis would be improved by further confirmation using western blot analysis.
Despite their limitations, our results confirm the importance of Bmp2 in the mechanism of peripheral sensitization of BCP. In this study, breast cancer cell injection led to upregulation of Bmp2 expression in DRG neurons, which was correlated with enhanced neuronal excitability and pain hypersensitivity. In vivo targeting of Bmp2 by siRNA attenuated pain hypersensitivity and ameliorated BCP in rats. Our data suggest that BMP2 antagonists may be effective for treatment of BCP hypersensitivity. 
